Treatment of blastomycosis with higher doses of fluconazole

Peter G. Pappas, Robert W. Bradsher, Carol A. Kauffman, Gretchen A. Cloud, Carolynn J. Thomas, G. Douglas Campbell, Stanley W. Chapman, Cheryl L Newman, William E. Dismukes

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Recent clinical data suggest that fluconazole at daily doses of 200 to 400 mg for at least 6 months is moderately effective therapy for non-life- threatening blastomycosis. To examine the usefulness of higher doses of fluconazole therapy for this disorder, we conducted a multicenter, randomized, open-label study to determine the efficacy and safety of two different daily doses of fluconazole (400 and 800 mg) in the treatment of non-life-threatening blastomycosis. Of 39 patients evaluable for efficacy analysis, 34 (87%) were successfully treated, including 89% and 85% of patients who received 400 and 800 mg, respectively. Five (83%) of six patients for whom prior antifungal therapy had failed were successfully treated. The mean duration of therapy was 8.9 months for successfully treated patients. Nineteen patients (48%) reported adverse events, although most were minor. We conclude that fluconazole at daily doses of 400 to 800 mg for at least 6 months is effective therapy for non-life-threatening blastomycosis.

Original languageEnglish (US)
Pages (from-to)200-205
Number of pages6
JournalClinical Infectious Diseases
Volume25
Issue number2
DOIs
StatePublished - Jan 1 1997
Externally publishedYes

Fingerprint

Blastomycosis
Fluconazole
Therapeutics
Safety

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Pappas, P. G., Bradsher, R. W., Kauffman, C. A., Cloud, G. A., Thomas, C. J., Campbell, G. D., ... Dismukes, W. E. (1997). Treatment of blastomycosis with higher doses of fluconazole. Clinical Infectious Diseases, 25(2), 200-205. https://doi.org/10.1086/514539

Treatment of blastomycosis with higher doses of fluconazole. / Pappas, Peter G.; Bradsher, Robert W.; Kauffman, Carol A.; Cloud, Gretchen A.; Thomas, Carolynn J.; Campbell, G. Douglas; Chapman, Stanley W.; Newman, Cheryl L; Dismukes, William E.

In: Clinical Infectious Diseases, Vol. 25, No. 2, 01.01.1997, p. 200-205.

Research output: Contribution to journalArticle

Pappas, PG, Bradsher, RW, Kauffman, CA, Cloud, GA, Thomas, CJ, Campbell, GD, Chapman, SW, Newman, CL & Dismukes, WE 1997, 'Treatment of blastomycosis with higher doses of fluconazole', Clinical Infectious Diseases, vol. 25, no. 2, pp. 200-205. https://doi.org/10.1086/514539
Pappas PG, Bradsher RW, Kauffman CA, Cloud GA, Thomas CJ, Campbell GD et al. Treatment of blastomycosis with higher doses of fluconazole. Clinical Infectious Diseases. 1997 Jan 1;25(2):200-205. https://doi.org/10.1086/514539
Pappas, Peter G. ; Bradsher, Robert W. ; Kauffman, Carol A. ; Cloud, Gretchen A. ; Thomas, Carolynn J. ; Campbell, G. Douglas ; Chapman, Stanley W. ; Newman, Cheryl L ; Dismukes, William E. / Treatment of blastomycosis with higher doses of fluconazole. In: Clinical Infectious Diseases. 1997 ; Vol. 25, No. 2. pp. 200-205.
@article{d8a8a56e17a947b0a37f2d46327c6964,
title = "Treatment of blastomycosis with higher doses of fluconazole",
abstract = "Recent clinical data suggest that fluconazole at daily doses of 200 to 400 mg for at least 6 months is moderately effective therapy for non-life- threatening blastomycosis. To examine the usefulness of higher doses of fluconazole therapy for this disorder, we conducted a multicenter, randomized, open-label study to determine the efficacy and safety of two different daily doses of fluconazole (400 and 800 mg) in the treatment of non-life-threatening blastomycosis. Of 39 patients evaluable for efficacy analysis, 34 (87{\%}) were successfully treated, including 89{\%} and 85{\%} of patients who received 400 and 800 mg, respectively. Five (83{\%}) of six patients for whom prior antifungal therapy had failed were successfully treated. The mean duration of therapy was 8.9 months for successfully treated patients. Nineteen patients (48{\%}) reported adverse events, although most were minor. We conclude that fluconazole at daily doses of 400 to 800 mg for at least 6 months is effective therapy for non-life-threatening blastomycosis.",
author = "Pappas, {Peter G.} and Bradsher, {Robert W.} and Kauffman, {Carol A.} and Cloud, {Gretchen A.} and Thomas, {Carolynn J.} and Campbell, {G. Douglas} and Chapman, {Stanley W.} and Newman, {Cheryl L} and Dismukes, {William E.}",
year = "1997",
month = "1",
day = "1",
doi = "10.1086/514539",
language = "English (US)",
volume = "25",
pages = "200--205",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Treatment of blastomycosis with higher doses of fluconazole

AU - Pappas, Peter G.

AU - Bradsher, Robert W.

AU - Kauffman, Carol A.

AU - Cloud, Gretchen A.

AU - Thomas, Carolynn J.

AU - Campbell, G. Douglas

AU - Chapman, Stanley W.

AU - Newman, Cheryl L

AU - Dismukes, William E.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - Recent clinical data suggest that fluconazole at daily doses of 200 to 400 mg for at least 6 months is moderately effective therapy for non-life- threatening blastomycosis. To examine the usefulness of higher doses of fluconazole therapy for this disorder, we conducted a multicenter, randomized, open-label study to determine the efficacy and safety of two different daily doses of fluconazole (400 and 800 mg) in the treatment of non-life-threatening blastomycosis. Of 39 patients evaluable for efficacy analysis, 34 (87%) were successfully treated, including 89% and 85% of patients who received 400 and 800 mg, respectively. Five (83%) of six patients for whom prior antifungal therapy had failed were successfully treated. The mean duration of therapy was 8.9 months for successfully treated patients. Nineteen patients (48%) reported adverse events, although most were minor. We conclude that fluconazole at daily doses of 400 to 800 mg for at least 6 months is effective therapy for non-life-threatening blastomycosis.

AB - Recent clinical data suggest that fluconazole at daily doses of 200 to 400 mg for at least 6 months is moderately effective therapy for non-life- threatening blastomycosis. To examine the usefulness of higher doses of fluconazole therapy for this disorder, we conducted a multicenter, randomized, open-label study to determine the efficacy and safety of two different daily doses of fluconazole (400 and 800 mg) in the treatment of non-life-threatening blastomycosis. Of 39 patients evaluable for efficacy analysis, 34 (87%) were successfully treated, including 89% and 85% of patients who received 400 and 800 mg, respectively. Five (83%) of six patients for whom prior antifungal therapy had failed were successfully treated. The mean duration of therapy was 8.9 months for successfully treated patients. Nineteen patients (48%) reported adverse events, although most were minor. We conclude that fluconazole at daily doses of 400 to 800 mg for at least 6 months is effective therapy for non-life-threatening blastomycosis.

UR - http://www.scopus.com/inward/record.url?scp=16944362231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16944362231&partnerID=8YFLogxK

U2 - 10.1086/514539

DO - 10.1086/514539

M3 - Article

C2 - 9332510

AN - SCOPUS:16944362231

VL - 25

SP - 200

EP - 205

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 2

ER -